WO2001014539A3 - Methods and compositions for the construction and use of fusion libraries - Google Patents

Methods and compositions for the construction and use of fusion libraries Download PDF

Info

Publication number
WO2001014539A3
WO2001014539A3 PCT/US2000/022906 US0022906W WO0114539A3 WO 2001014539 A3 WO2001014539 A3 WO 2001014539A3 US 0022906 W US0022906 W US 0022906W WO 0114539 A3 WO0114539 A3 WO 0114539A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
enzyme
nam
fusion
encoding
Prior art date
Application number
PCT/US2000/022906
Other languages
French (fr)
Other versions
WO2001014539A2 (en
Inventor
Min Li
Original Assignee
Univ Johns Hopkins Med
Min Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med, Min Li filed Critical Univ Johns Hopkins Med
Priority to EP00955779A priority Critical patent/EP1212411A2/en
Priority to KR1020027002204A priority patent/KR20020059370A/en
Priority to AU67925/00A priority patent/AU781478B2/en
Priority to JP2001518853A priority patent/JP2003507063A/en
Priority to CA002382483A priority patent/CA2382483A1/en
Publication of WO2001014539A2 publication Critical patent/WO2001014539A2/en
Publication of WO2001014539A3 publication Critical patent/WO2001014539A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention provides libraries of fusion nucleic acids each comprising nucleic acid encoding a nucleic acid modification (NAM) enzyme, and nucleic acid encoding a candidate protein. Also provided is a library of fusion polypeptides comprising a nucleic acid modification (NAM) enzyme and a candidate protein. A library of expression vectors is provided each comprising (i) a fusion nucleic acid comprising a nucleic acid encoding a nucleic acid modification (NAM) enzyme, and nucleic acid encoding a candidate protein, and (ii) an EAS. At least two of the candidate proteins are different. Preferably, the NAM enzyme is a Rep protein. Also preferably, the EAS is greater than 20 nucleotides in length. Similarly, preferred embodiments utilize fusion nucleic acids comprising nucleic acids encoding presentation structures, nucleic acids encoding labels or nucleic acids encoding targeting sequences. The invention also provides libraries of nucleic acid/protein (NAP) conjugates each comprising a fusion polypeptide comprising a NAM enzyme and a candidate protein. The NAP conjugates also comprise an expression vector comprising a fusion nucleic acid comprising a fusion nucleic acid comprising a nucleic acid encoding a NAM enzyme, a nucleic acid encoding a candidate protein, and an enzyme attachment sequence (EAS) that is recognized by the NAM enzyme. The EAS and the NAM enzyme are covalently attached. Libraries of host cells and methods of screening are also provided.
PCT/US2000/022906 1999-08-20 2000-08-18 Methods and compositions for the construction and use of fusion libraries WO2001014539A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00955779A EP1212411A2 (en) 1999-08-20 2000-08-18 Methods and compositions for the construction and use of fusion libraries
KR1020027002204A KR20020059370A (en) 1999-08-20 2000-08-18 Methods and compositions for the construction and use of fusion libraries
AU67925/00A AU781478B2 (en) 1999-08-20 2000-08-18 Methods and compositions for the construction and use of fusion libraries
JP2001518853A JP2003507063A (en) 1999-08-20 2000-08-18 Methods and compositions for constructing and using fusion libraries
CA002382483A CA2382483A1 (en) 1999-08-20 2000-08-18 Methods and compositions for the construction and use of fusion libraries

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15000499P 1999-08-20 1999-08-20
US60/150,004 1999-08-20
US20913000P 2000-06-02 2000-06-02
US60/209,130 2000-06-02

Publications (2)

Publication Number Publication Date
WO2001014539A2 WO2001014539A2 (en) 2001-03-01
WO2001014539A3 true WO2001014539A3 (en) 2001-09-27

Family

ID=26847232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022906 WO2001014539A2 (en) 1999-08-20 2000-08-18 Methods and compositions for the construction and use of fusion libraries

Country Status (7)

Country Link
EP (1) EP1212411A2 (en)
JP (1) JP2003507063A (en)
KR (1) KR20020059370A (en)
CN (1) CN1378593A (en)
AU (1) AU781478B2 (en)
CA (1) CA2382483A1 (en)
WO (1) WO2001014539A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032823A1 (en) 1998-12-02 2000-06-08 Phylos, Inc. Dna-protein fusions and uses thereof
US20030036643A1 (en) * 2000-09-14 2003-02-20 Jin Cheng He Methods and compositions for the construction and use of fusion libraries
WO2002022826A2 (en) * 2000-09-14 2002-03-21 Xencor, Inc. Methods and compositions for the construction and use of fusion libraries
WO2002066653A2 (en) * 2000-12-14 2002-08-29 Xencor Procaryotic libraries and uses
WO2002068698A2 (en) * 2001-02-22 2002-09-06 Xencor, Inc. Use of nucleic acid libraries to create toxicological profiles
AU2002251999A1 (en) * 2001-02-22 2002-09-12 Xencor Methods and compositions for the construction and use of fusion libraries using computational protein design methods
US20020168640A1 (en) * 2001-02-22 2002-11-14 Min Li Biochips comprising nucleic acid/protein conjugates
CA2864537C (en) 2001-11-13 2016-11-29 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
WO2003100100A1 (en) * 2002-05-24 2003-12-04 Somagenics, Inc. Methods and compositions for production of directed sequence libraries
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
EP1701772A4 (en) 2003-11-21 2012-03-28 Univ Johns Hopkins Biomolecule partition motifs and uses thereof
WO2005086679A2 (en) 2004-03-05 2005-09-22 Medical College Of Ohio Methods and compositions for assessing nucleic acids and alleles
WO2005106036A2 (en) 2004-04-12 2005-11-10 Medical College Of Ohio Methods and compositions for assaying analytes
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
MX2010000944A (en) * 2007-07-26 2010-08-31 Amsterdam Molecular Therapeutics Bv Baculoviral vectors comprising repeated coding sequences with differential codon biases.
EP4098661A1 (en) 2007-12-26 2022-12-07 Xencor, Inc. Fc variants with altered binding to fcrn
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
GB2505237A (en) * 2012-08-24 2014-02-26 Stefan Grimm Method of screening for therapeutic agents using cell lines including a reference cell line
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191A4 (en) 2014-11-05 2018-08-01 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
CN114717264A (en) 2014-11-14 2022-07-08 沃雅戈治疗公司 Compositions and methods for treating Amyotrophic Lateral Sclerosis (ALS)
JP6863891B2 (en) 2014-11-14 2021-04-21 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Regulatory polynucleotide
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
ES2826880T3 (en) * 2015-05-11 2021-05-19 Illumina Inc Platform for the discovery and analysis of therapeutic agents
US10983110B2 (en) 2015-12-02 2021-04-20 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
BR112018073384A2 (en) 2016-05-18 2019-03-06 Voyager Therapeutics, Inc. modulating polynucleotides
WO2017201258A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
GB201702938D0 (en) * 2017-02-23 2017-04-12 Univ Southampton Methods of generating and screening compartmentalised peptides libraries
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
JP7229989B2 (en) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド Trajectory array guide system
MX2020001187A (en) 2017-08-03 2020-10-05 Voyager Therapeutics Inc Compositions and methods for delivery of aav.
WO2019079240A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN110452303B (en) * 2019-08-08 2022-03-04 中国科学院武汉病毒研究所 Method for covalently linking nucleic acid and peptide or protein and application thereof
WO2021117874A1 (en) * 2019-12-13 2021-06-17 中外製薬株式会社 System for detecting extracellular purinergic receptor ligand and nonhuman animal having same transferred thereinto
CN111704655A (en) * 2020-04-24 2020-09-25 吉林农业大学 Goose parvovirus protein capable of inducing goose embryo fibroblast apoptosis and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1998023781A1 (en) * 1996-11-26 1998-06-04 Johns Hopkins University Ligand detection system and methods of use thereof
US5856090A (en) * 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5856090A (en) * 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
WO1998023781A1 (en) * 1996-11-26 1998-06-04 Johns Hopkins University Ligand detection system and methods of use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CODY C W ET AL: "CHEMICAL STRUCTURE OF THE HEXAPEPTIDE CHROMOPHORE OF THE AEQUOREA GREEN-FLUORESCENT PROTEIN", BIOCHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 32, no. 5, 2 February 1993 (1993-02-02), pages 1212 - 1218, XP002030240, ISSN: 0006-2960 *
CULL M G ET AL: "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1992 MAR 1) 89 (5) 1865-9., XP002043736 *
INOUYE S ET AL: "AEQUOREA GREEN FLUORESCENT PROTEIN EXPRESSION OF THE GENE AND FLUORESCENCE CHARACTERISTICS OF THE RECOMBINANT PROTEIN", FEBS LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 341, no. 2/03, 21 March 1994 (1994-03-21), pages 277 - 280, XP002030244, ISSN: 0014-5793 *
MARTIN ET AL: "THE AFFINITY-SELECTION OF A MINIBODY POLYPEPTIDE INHIBITOR OF HUMAN INTERLEUKIN 6", EMBO JOURNAL,GB,OXFORD UNIVERSITY PRESS, SURREY, no. 13, 1994, pages 5303 - 5309, XP002076260, ISSN: 0261-4189 *
MCCONNELL S J ET AL: "Tendamistat as a scaffold for conformationally constrained phage peptide libraries.", JOURNAL OF MOLECULAR BIOLOGY, (1995 JUL 21) 250 (4) 460-70., XP000985692 *
MICELI R ET AL: "The coiled coil stem loop miniprotein as a presentation scaffold.", DRUG DESIGN AND DISCOVERY, (1996 APR) 13 (3-4) 95-105., XP000985689 *
SILHAVY T J ET AL: "USES OF LAC FUSIONS FOR THE STUDY OF BIOLOGICAL PROBLEMS", MICROBIOLOGICAL REVIEWS,AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC,US, vol. 49, no. 4, 1 December 1985 (1985-12-01), pages 398 - 418, XP000570644, ISSN: 0146-0749 *
SPENCER D M ET AL: "CONTROLLING SIGNAL TRANSDUCTION WITH SYNTHETIC LIGANDS", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 262, 12 November 1993 (1993-11-12), pages 1019 - 1024, XP000568878, ISSN: 0036-8075 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn

Also Published As

Publication number Publication date
KR20020059370A (en) 2002-07-12
EP1212411A2 (en) 2002-06-12
CN1378593A (en) 2002-11-06
AU781478B2 (en) 2005-05-26
CA2382483A1 (en) 2001-03-01
AU6792500A (en) 2001-03-19
JP2003507063A (en) 2003-02-25
WO2001014539A2 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
WO2001014539A3 (en) Methods and compositions for the construction and use of fusion libraries
WO1999055868A3 (en) Fizz proteins
WO1999066025A3 (en) Mtbx protein and nucleic acid molecules and uses therefor
WO1998056927A3 (en) Nucleic acids encoding polypeptide having protease activity
EP1009752A4 (en) Novel molecules of the tango-77 related protein family and uses thereof
WO2000052047A3 (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
DK1025237T3 (en) Human checkpoint kinase, hCDS1, preparations and methods
WO2000019988A8 (en) NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
WO2000046236A3 (en) Novel rgs-containing molecules and uses thereof
WO2000012544A3 (en) Novel irap-bp polypeptide and nucleic acid molecules and uses therefor
WO2001018216A3 (en) 26176, a novel calpain protease and uses thereof
WO1995013386A3 (en) Tyrosinase-activator protein fusion enzyme
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
CA2251262A1 (en) Nucleic acid encoding a nervous tissue sodium channel
WO2000008045A3 (en) Novel molecules of the tango-93-related protein family and uses thereof
WO1999054437A3 (en) Novel molecules of the t125-related protein family and uses thereof
WO2003029434A3 (en) Novel molecules of the hkid-1-related protein family and uses thereof
WO2001077151A3 (en) Fdrg proteins and nucleic acid molecules and uses therefor
WO2000018890A3 (en) Protein phosphatase molecules and uses therefor
WO2002074960A3 (en) 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
WO2001073074A3 (en) 18806, a novel trypsin serine protease-like molecule and uses thereof
WO1999062943A3 (en) Novel molecules of the aip-related protein family and uses thereof
WO2001083523A3 (en) Stmst protein and nucleic acid molecules and uses therefor
WO2001000879A8 (en) Novel kinases and uses thereof
WO1999067387A3 (en) Novel mp-7 protein and nucleic acid molecules and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 67925/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2382483

Country of ref document: CA

Ref document number: 1020027002204

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000955779

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 00814124X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000955779

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027002204

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 67925/00

Country of ref document: AU